Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoFIND: [68Ga]-NeoBOMB1 in GRPR-Positive Solid Tumors
NCT03724253Phase 2Terminated
- Sponsor
- Advanced Accelerator Applications
- Start
- Jul 2018
- Primary completion
- Jun 2019
- Modality
- Peptide-Drug Conjugates
- Countries
- 2
01
Overview
A Phase 2 trial of gallium Ga 68 DOTA-NeoBOMB1 in breast cancer, prostate cancer (PCa), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sponsored by Advanced Accelerator Applications. Started Jul 2018; status: terminated.
02
Drugs
gallium Ga 68 DOTA-NeoBOMB1
03
Conditions
breast cancerprostate cancer (PCa)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03724253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724253.